Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

NCT01623596

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Cullman, Alabama, United States
  • Novartis Investigative Site Phoenix, Arizona, United States
  • Novartis Investigative Site Sun City, Arizona, United States
  • Novartis Investigative Site Tucson, Arizona, United States
View all 123 locations
View Trial Details
Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Huntsville, Alabama, United States
  • research Site Mesa, Arizona, United States
  • Research Site Phoenix, Arizona, United States
View all 246 locations
View Trial Details
Completed

CLARITY Extension Study

NCT00641537

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Boulder, Colorado, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Chicago, Illinois, United States
  • Research Site Northbrook, Illinois, United States
View all 116 locations
View Trial Details
Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

NCT03177083

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Hospital Fernando Fonseca Amadora, Portugal
  • Hospital de Braga Braga, Portugal
  • Centro Hospitalar Cova da Beira Covilha, Portugal
  • Hospital Evora Evora, Portugal
View all 15 locations
View Trial Details
Completed

Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis

NCT02424396

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Centre d'investigation Clinique - Pitié salpêtrière Paris, France
  • Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP Paris, France
  • Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP Paris, France
View Trial Details
Completed

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03093324

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Alkermes Investigational Site Cullman, Alabama, United States
  • Alkermes Investigational Site Phoenix, Arizona, United States
  • Alkermes Investigational Site Tucson, Arizona, United States
  • Alkermes Investigational Site Long Beach, California, United States
View all 67 locations
View Trial Details

Related conditions